Skip to main content

Table 2 Summary of results

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

  Ceftolozane/tazobactam Piperacillin/tazobactam Incremental
Ceftolozane/tazobactam - Piperacillin/tazobactam
Total costs per patient (USD 2015) $36,413 $36,028 $385
Total QALYs (undiscounted) per patient 11.82 11.74 0.08
Total QALYs (discounted) per patient 9.19 9.13 0.06
Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained)    $6128
Hospitalization days saved per patient    0.25
  1. QALY Quality-adjusted life year